Zacks Investment Research
18 Jun 2026, 17:50 UTC · 2h ago
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
18 Jun 2026, 17:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Cencora reduced its fiscal 2026 revenue growth outlook from 7-9% to 4-6%. — Lowering top-line guidance is a primary driver for the stock's 18% YTD decline and signals slower growth momentum.
-0.60Cencora raised its adjusted EPS guidance to $17.70-$17.90 despite lower revenue expectations. — Increased earnings guidance suggests improving margins and operating leverage, which can offset revenue headwinds.
+0.40The acquisition of OneOncology in February 2026 increased consolidated gross profit margins by 45 basis points. — Direct evidence of a strategic acquisition contributing to immediate margin expansion and diversification into physician services.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company has gained 10.1% year to date, outperforming its peer Cencora.
Despite a YTD price decline and lowered revenue guidance, the company raised EPS guidance and showed improving profitability and strategic growth.
Mentioned as a peer with a slight YTD loss, but no specific operational news was provided.
[mutual] Cardinal Health is identified as one of Cencora's closest peers.
[mutual] McKesson is identified as one of Cencora's closest peers.
[mutual] Both are listed as closest peers to Cencora in the pharmaceutical distribution industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
41m ago
